Abstract
ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase. After Crizotinib approval by FDA for the management of ALK-rearranged lung cancer, ROS1-positive tumors have been focused. Although significant advancements have been achieved in understanding ROS1 function and its signaling pathways plus recent discovery of small molecules modulating ROS1 protein, a vital need of medicinal chemistry efforts is still required to produce selective and potent ROS1 inhibitors as an important therapeutic strategy for different human malignancies. This review focuses on the current knowledge about different scaffolds targeting ROS1 rearrangements, methods to synthesis, and some biological data about the most potent compounds that have delivered various scaffold structures.
Keywords: ROS1 kinase, receptor tyrosine kinase, cancer, inhibitor, translocation.
Current Medicinal Chemistry
Title:ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Volume: 23 Issue: 2
Author(s): M.M. Al-Sanea, A.Z. Abdelazem, B.S. Park, K.H. Yoo, T. Sim, Y.J. Kwon and S.H. Lee
Affiliation:
Keywords: ROS1 kinase, receptor tyrosine kinase, cancer, inhibitor, translocation.
Abstract: ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase. After Crizotinib approval by FDA for the management of ALK-rearranged lung cancer, ROS1-positive tumors have been focused. Although significant advancements have been achieved in understanding ROS1 function and its signaling pathways plus recent discovery of small molecules modulating ROS1 protein, a vital need of medicinal chemistry efforts is still required to produce selective and potent ROS1 inhibitors as an important therapeutic strategy for different human malignancies. This review focuses on the current knowledge about different scaffolds targeting ROS1 rearrangements, methods to synthesis, and some biological data about the most potent compounds that have delivered various scaffold structures.
Export Options
About this article
Cite this article as:
Al-Sanea M.M., Abdelazem A.Z., Park B.S., Yoo K.H., Sim T., Kwon Y.J. and Lee S.H., ROS1 Kinase Inhibitors for Molecular-Targeted Therapies, Current Medicinal Chemistry 2016; 23 (2) . https://dx.doi.org/10.2174/0929867322666151006093623
DOI https://dx.doi.org/10.2174/0929867322666151006093623 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ETS Proteins and MMPs: Partners in Invasion and Metastasis
Medicinal Chemistry Reviews - Online (Discontinued) Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets MADD Expression in Lung Adenocarcinoma and its Impact on Proliferation and Apoptosis of Lung Adenocarcinoma Cells
Combinatorial Chemistry & High Throughput Screening Targeting miR-21 Induces Autophagy and Chemosensitivity of Leukemia Cells
Current Drug Targets Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design Amino Acid Derived Prodrugs: An Approach to Improve the Bioavailability of Clinically Approved Drugs
Current Topics in Medicinal Chemistry Multidimensional Role of Inulin as Synbiotic, Drug Carrier and Synergistic Adjuvant for the Colonic Delivery of 5-FU
Drug Delivery Letters Recent Advances in Liposome Techniques and their Applications in Arthritis
Recent Patents on Biomedical Engineering (Discontinued) Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Design, Synthesis and Biological Evaluation of Cyanopyridines, Pyridopyrazolopyrimidines and Pyridopyrazolotriazines as Potential Anticancer Agents
Current Organic Synthesis Design of Magnetic Nanoparticles-Assisted Drug Delivery System
Current Pharmaceutical Design Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Sleep Disturbances in Lung Cancer Patients
Current Respiratory Medicine Reviews Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Current Diabetes Reviews Fibroblast Growth Factors in Development and Cancer: Insights from the Mammary and Prostate Glands
Current Drug Targets Synthesis and Cytotoxic Activities of Difluoro-Dimethoxy Chalcones
Anti-Cancer Agents in Medicinal Chemistry Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?
Current Medicinal Chemistry Design, Synthesis and Anticancer Evaluation of 1,2,4-Oxadiazole Bearing Isoxazole-Pyrazole Derivatives
Letters in Organic Chemistry Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets
Current Drug Targets